Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Pyk2 inhibitor

DRUG CLASS:

Pyk2 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

KRAS wild-type	Ovarian Cancer	KRAS wild-type	Ovarian Cancer	VS-6766 + VS-6063 Sensitive: B - Late Trials VS-6766 + VS-6063 Sensitive : B	VS-6766 + VS-6063 Sensitive: B - Late Trials VS-6766 + VS-6063 Sensitive : B
KRAS G12V	Ovarian Serous Adenocarcinoma	KRAS G12V	Ovarian Serous Adenocarcinoma	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2
KRAS mutation	Ovarian Cancer	KRAS mutation	Ovarian Cancer	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2
KRAS G12V	Ovarian Cancer	KRAS G12V	Ovarian Cancer	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	SY-707 Sensitive: C2 – Inclusion Criteria SY-707 Sensitive : C2	SY-707 Sensitive: C2 – Inclusion Criteria SY-707 Sensitive : C2
KRAS G12D	Ovarian Serous Adenocarcinoma	KRAS G12D	Ovarian Serous Adenocarcinoma	VS-6766 + VS-6063 Sensitive: C3 – Early Trials VS-6766 + VS-6063 Sensitive : C3	VS-6766 + VS-6063 Sensitive: C3 – Early Trials VS-6766 + VS-6063 Sensitive : C3
KRAS G12A	Ovarian Serous Adenocarcinoma	KRAS G12A	Ovarian Serous Adenocarcinoma	VS-6766 + VS-6063 Sensitive: C3 – Early Trials VS-6766 + VS-6063 Sensitive : C3	VS-6766 + VS-6063 Sensitive: C3 – Early Trials VS-6766 + VS-6063 Sensitive : C3
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + VS-6766 + VS-6063 Sensitive: D – Preclinical sotorasib + VS-6766 + VS-6063 Sensitive : D	sotorasib + VS-6766 + VS-6063 Sensitive: D – Preclinical sotorasib + VS-6766 + VS-6063 Sensitive : D